Welcome to our dedicated page for Clearmind Medici news (Ticker: CMND), a resource for investors and traders seeking the latest updates and insights on Clearmind Medici stock.
Clearmind Medicine Inc. develops clinical-stage neuroplastogen-derived therapeutics focused on mental health and substance-use disorders. News for CMND centers on CMND-100, the company's proprietary non-hallucinogenic MEAI-based oral drug candidate for Alcohol Use Disorder, including clinical-trial safety, tolerability, pharmacokinetic and preliminary efficacy updates from a multinational Phase I/IIa study.
Company updates also cover intellectual-property activity for psychedelic and neuroplastogen compounds, including patent applications and licensed development rights tied to PTSD and other mental health disorders. Additional recurring themes include FDA-related clinical communications, data-safety monitoring reviews, clinical-site progress and scientific presentations around MEAI.
Clearmind Medicine (Nasdaq: CMND) welcomed President Trump’s April 18, 2026 Executive Order prioritizing FDA review and expanded access pathways for certain psychedelic breakthrough therapies.
The company highlighted its non‑hallucinogenic neuroplastogen MEAI (CMND-100), its naming in H.R. 7091 (Feb 2026), and ongoing FDA‑approved Phase I/IIa trials at Yale and Johns Hopkins.
Clearmind Medicine (Nasdaq: CMND) announced that CMND-100, its non-hallucinogenic MEAI-based oral candidate for Alcohol Use Disorder, met the primary safety and tolerability endpoint in the FDA-approved Phase I/IIa dose-escalation trial on April 20, 2026.
Data from the third cohort showed a high safety profile, favorable overall tolerability, and no serious adverse events, including at the highest dose tested, supporting continued clinical advancement.
Clearmind Medicine (Nasdaq: CMND) said an independent Data and Safety Monitoring Board gave a positive recommendation to continue its FDA-approved Phase I/IIa trial of CMND-100 for Alcohol Use Disorder after the third cohort.
The DSMB found CMND-100 well tolerated with no serious adverse events, and the company will advance to a fourth cohort testing an increased 160mg dose.
Clearmind Medicine (Nasdaq: CMND) reported that its oral candidate CMND-100 met the primary safety and tolerability endpoint in an FDA-approved Phase I/IIa dose-escalation trial for Alcohol Use Disorder on April 14, 2026. The third cohort showed a high safety profile with no serious adverse events and continued favorable tolerability, including at the highest dose tested to date. The multinational, multicenter study assessed safety, tolerability, pharmacokinetics, and preliminary efficacy; meeting the primary endpoint supports continued clinical advancement of CMND-100 as a potential non-hallucinogenic AUD treatment.
Clearmind Medicine (Nasdaq: CMND) announced on March 30, 2026 the successful completion of treatment and follow-up for 18 participants in its FDA‑approved Phase I/IIa trial of CMND-100, a non‑hallucinogenic MEAI‑based oral candidate for Alcohol Use Disorder.
The company also treated four additional participants at its Tel Aviv site, and the multinational trial includes sites at Yale, Johns Hopkins, Tel Aviv Sourasky Medical Center, and Hadassah Medical Center.
Clearmind Medicine (Nasdaq: CMND) filed a patent application in India on March 27, 2026 for next‑generation, non‑hallucinogenic neuroplastogen‑derived compounds targeting mental health disorders and addiction.
The filing, with the Indian Patent Office, expands the company's global intellectual property portfolio and builds on its exclusive worldwide licensing agreement with Yissum, seeking protection for novel compounds designed to address limitations of classical psychedelics and enable potentially safer, scalable treatments.
Clearmind Medicine (Nasdaq: CMND) reported successful ongoing treatment of participants in the third cohort of its FDA-approved Phase I/IIa trial of CMND-100 for Alcohol Use Disorder (AUD) as of March 19, 2026. U.S. sites at Yale and Johns Hopkins continue treatment with no serious adverse events reported to date.
The multinational, multicenter study evaluates safety, tolerability, pharmacokinetics and preliminary efficacy of the company’s non-hallucinogenic, MEAI-based oral candidate in patients with moderate to severe AUD.
Clearmind Medicine (Nasdaq: CMND) announced publication of six patents in Hong Kong on March 17, 2026 covering proprietary combination therapies that integrate Palmitoylethanolamide (PEA) with six psychedelic compounds.
The patents protect formulations combining PEA with MDMA, LSD, ketamine, ibogaine, psilocybin, and DMT, and reflect a sourcing partnership with NeuroThera Labs. The company describes these combinations as intended to enhance therapeutic potential, safety, tolerability, and neuroplasticity profiles for mental health and neurological indications.
Clearmind Medicine (Nasdaq: CMND) on March 13, 2026 filed a patent application with Hong Kong IPD for a combination therapy pairing proprietary MEAI with Palmitoylethanolamide (PEA) to treat major depressive disorder (MDD).
The filing notes the PEA supply via a partnership with NeuroThera Labs (TSXV: NTLX), a SciSparc subsidiary, and positions the MEAI-PEA synergy as a non-hallucinogenic neuroplastogen approach targeting an MDD market projected above $25 billion by 2030.
Clearmind Medicine (Nasdaq: CMND) announced continued enrollment for Cohort 3 of its FDA-approved Phase I/IIa trial of CMND-100 for Alcohol Use Disorder on March 11, 2026. The move follows positive topline results from Cohort 2 and unanimous DSMB approval to proceed.
The multinational, multicenter study will expand recruitment at Yale, Johns Hopkins and Tel Aviv Sourasky Medical Center to evaluate safety, tolerability, pharmacokinetics and preliminary efficacy of the non-hallucinogenic MEAI-derived oral candidate.